Beyond the current knowledge on sarcopenia: new insight on neuromuscular factors.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Neurofilament-light chains (NF-L), a biomarker of neuronal damage, is increased in patients with severe sarcopenia: results of the SarcoPhAge study.Aging clinical and experimental research · 2023
   Article
2. Functional brain changes in sarcopenia: evidence for differential central neural mechanisms in dynapenic older women.Aging clinical and experimental research · 2023
   Article
3. The syndromic triad of COVID-19, type 2 diabetes, and malnutrition.Frontiers in nutrition · 2023
   Review
4. Effects of high-intensity interval training on lean mass, strength, and power of the lower limbs in healthy old and young people.Frontiers in physiology · 2023
   Article
5. Rehabilitation of Older Adults with Sarcopenia: From Cell to Functioning.Progress in rehabilitation medicine · 2022
   Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as